Tazobactam (sodium salt) (Synonyms: CL-307579,YTR 830) |
Catalog No.GC10366 |
El tazobactam (sal de sodio) es un antibiÓtico de la clase de los inhibidores de las betalactamasas.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 89785-84-2
Sample solution is provided at 25 µL, 10mM.
Tazobactam is a β-lactamase inhibitor [1]. Tazobactam shows intrinsic activity against Acinetobacter strains.
The β-Lactamases are responsible for resistance to penicillins, extended-spectrum cephalosporins, monobactams, and carbapenems. In order to overcome β-lactamase-mediated resistance, β-lactamase inhibitors have been introduced into clinical practice [2].
Tazobactam alone showed an MIC of ≤ 8 mg/liter (range 2 to 32 mg/liter) against 29 of the 38 strains [1]. Tazobactam in combination with the ureidopenicillin, piperacillin successfully restored the activity of piperacillin against β-lactamase-producing bacteria [3]. Tazobactam exhibited inhibitory activity and protected piperacillin against Richmond and Sykes types II, III, IV and V β-lactamases, staphylococcal penicillinase and extended-spectrum β-lactamases [3]. Tazobactam showed species-specific activity against class I chromosomally-mediated enzymes [3].
Preliminary clinical data indicated that the fixed combination of piperacillin /tazobactam was effective in the treatment of moderate to severe polymicrobial infections, including skin, intra-abdominal and soft-tissue and lower respiratory tract infections [3]. Piperacillin/tazobactam in combination with an aminoglycoside was effective in the empirical treatment of fever in patients with neutropenia. In phase III trials, piperacillin/tazobactam showed a tolerability profile typical of a penicillin agent [3].
References:
[1] Higgins P G, Wisplinghoff H, Stefanik D, et al. In vitro activities of the β-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with β-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains[J]. Antimicrobial agents and chemotherapy, 2004, 48(5): 1586-1592.
[2] Drawz S M, Bonomo R A. Three decades of β-lactamase inhibitors[J]. Clinical microbiology reviews, 2010, 23(1): 160-201.
[3] Perry C M, Markham A. Piperacillin/tazobactam[J]. Drugs, 1999, 57(5): 805-843.
Average Rating: 5
(Based on Reviews and 5 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *